PR Newswire Clinical TrialsOriginal article
XYRA Announces Issuance of US Patent to Reduce the Risk of Heart Failure or Strokes by Reducing the Number and Duration of Atrial Fibrillations
Patent ExpiryapprovedbudiodaronePositive
AI Analysis
Summary
XYRA LLC announced the issuance of US Patent No. 12,551,706 for dose-adjusted budiodarone in treating atrial fibrillation with monitoring to reduce heart failure and stroke risk.
Outcome Details
US Patent No. 12,551,706 issued protecting dose-adjusted budiodarone for atrial fibrillation treatment with monitoring to reduce heart failure or stroke risk
Importance:4/10
Sentiment:
0.60
patent issuanceatrial fibrillationintellectual propertycardiovascular
Read the original article
Published by PR Newswire Clinical Trials on March 4, 2026 8:00 AM